Currently Enrolling Trials
A three month, 22.5 mg dosage of Lupron Depot was approved as a treatment for advanced-stage prostate cancer.
In clinical trials, the safety and efficacy of Lupron Depot (three month, 22.5 mg) were similar to that of the original daily subcutaneous injection and the monthly depot formulation.
The most common side effect reported was hot flashes (58.5%). Like other treatment options, it may also cause impotence.
Mechanism of Action
Lupron Depot (three month, 22.5 mg) works by shutting down the production of the hormone testosterone, which plays a significant role in the growth of prostate cancer. Decreasing the levels of testosterone in the body also alleviates the bone pain and urinary problems that may be associated with metastatic prostate cancer.